U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951463) titled 'A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer' on Nov. 16.
Brief Summary: To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.
Study Start Date: Dec. 31
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer
Intervention:
DRUG: Glumetinib Tablets
Glumetinib 300 mg QD orally under fasting conditions
DRUG: Placebo
Placebo 300 mg QD orally under fasting conditions
DRUG: Osimertinib Mesylate Tablets
Administered orally...